Tilray Brands, Inc. (TLRY) Current Ratio
- Current ratio · latest quarter: Value 2.21×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.21× | Current assets / current liabilities. $792.13M ÷ $358.38M ≈ 2.21× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 792.13M USD | Assets, Current |
| Current obligations | 358.38M USD | Liabilities, Current |
| Cash and equivalents | 225.98M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 5.29M USD | Marketable Securities, Current |
| Customer receivables | 189.17M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 301.19M USD | Inventory, Net |
| Payables | 114.54M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $792.13M | $358.38M | $225.98M | $5.29M | $189.17M | $301.19M | $114.54M | (m) | 2.21× |
| 2026-02-28 | $718.76M | $257.54M | $204.62M | $15.31M | $118.37M | $292.30M | $115.33M | (m) | 2.79× |
| 2025-12-31 | $688.63M | $280.30M | $221.67M | $34.70M | $121.49M | $270.88M | (m) | (m) | 2.46× |
| 2025-11-30 | $729.32M | $259.31M | $246.70M | $44.85M | $109.07M | $283.20M | $114.50M | (m) | 2.81× |
| 2025-08-31 | $701.14M | $267.63M | $264.83M | $0.00 | $107.08M | $282.79M | $110.80M | (m) | 2.62× |
| 2025-05-31 | $688.63M | $280.30M | $221.67M | $34.70M | $121.49M | $270.88M | $107.35M | (m) | 2.46× |
| 2024-12-31 | $686.29M | $262.17M | $199.96M | $48.46M | $103.37M | $263.40M | (m) | (m) | 2.62× |
| 2024-11-30 | $707.34M | $278.52M | $189.70M | $62.55M | $112.74M | $266.01M | $99.08M | (m) | 2.54× |
| 2024-08-31 | $725.88M | $293.55M | $205.19M | $74.87M | $104.04M | $264.30M | $101.87M | (m) | 2.47× |
| 2024-05-31 | $677.71M | $299.17M | $228.34M | $32.18M | $101.69M | $252.09M | $105.39M | (m) | 2.27× |
| 2024-02-29 | $631.21M | $329.10M | $146.25M | $79.61M | $89.54M | $244.14M | $90.16M | (m) | 1.92× |
| 2023-12-31 | $677.71M | $299.17M | $228.34M | $32.18M | $101.69M | $252.09M | (m) | (m) | 2.27× |
| 2023-11-30 | $642.03M | $394.99M | $143.37M | $116.42M | $90.60M | $252.70M | $88.36M | (m) | 1.63× |
| 2023-08-31 | $829.25M | $537.27M | $177.52M | $287.33M | $82.08M | $232.07M | $78.97M | (m) | 1.54× |
| 2023-05-31 | $773.03M | $432.98M | $206.63M | $241.90M | $86.23M | $200.55M | $70.82M | (m) | 1.79× |
| 2023-02-28 | $758.51M | $469.68M | $165.00M | $243.29M | $78.34M | $202.80M | $67.06M | (m) | 1.61× |
| 2022-11-30 | $814.71M | $426.50M | $190.22M | $243.29M | $89.70M | $240.95M | $75.72M | (m) | 1.91× |
| 2022-08-31 | $910.88M | $273.26M | $490.64M | (m) | $98.35M | $244.65M | $75.84M | $64.10M | 3.33× |
| 2022-05-31 | $803.50M | $280.34M | $415.91M | $0.00 | $95.28M | $245.53M | $68.60M | (m) | 2.87× |
| 2022-03-31 | $803.50M | $280.34M | $415.91M | $0.00 | $95.28M | $245.53M | (m) | (m) | 2.87× |
| 2022-02-28 | $695.78M | $282.43M | $279.21M | (m) | $89.89M | $273.29M | $70.25M | $70.18M | 2.46× |
| 2021-11-30 | $708.28M | $314.93M | $331.78M | (m) | $84.58M | $233.02M | $64.98M | $31.51M | 2.25× |
| 2021-08-31 | $844.62M | $526.83M | $376.30M | (m) | $97.18M | $251.51M | $61.99M | $30.84M | 1.60× |
| 2021-05-31 | $883.61M | $401.24M | $488.47M | (m) | $87.31M | $256.43M | $57.71M | $36.62M | 2.20× |
| 2021-03-31 | $571.97M | $283.99M | $416.37M | (m) | $28.30M | $96.54M | $48.29M | (m) | 2.01× |
| 2020-12-31 | $347.02M | $181.28M | $189.70M | (m) | $29.03M | $93.64M | $17.78M | (m) | 1.91× |
| 2020-09-30 | $304.88M | $133.53M | $155.21M | (m) | $24.80M | $89.92M | $26.14M | (m) | 2.28× |
| 2020-06-30 | $289.80M | $163.67M | $137.21M | (m) | $26.61M | $93.09M | $22.20M | (m) | 1.77× |
| 2020-05-31 | $581.63M | $119.89M | $360.65M | (m) | $37.93M | $139.78M | $41.16M | $6.14M | 4.85× |
| 2020-03-31 | $338.97M | $171.37M | $173.99M | (m) | $38.32M | $95.59M | $23.91M | (m) | 1.98× |
| 2019-12-31 | $259.03M | $92.43M | $96.79M | (m) | $36.20M | $87.86M | $39.13M | (m) | 2.80× |
| 2019-09-30 | $330.68M | $130.20M | $100.16M | (m) | $36.04M | $110.49M | $58.69M | (m) | 2.54× |
| 2019-06-30 | $358.63M | $175.91M | $184.55M | (m) | $24.61M | $75.32M | $24.37M | (m) | 2.04× |
| 2019-03-31 | $399.59M | $170.36M | $294.20M | (m) | $19.71M | $48.71M | $17.18M | (m) | 2.35× |
| 2018-12-31 | $554.30M | $25.94M | $487.25M | (m) | $16.52M | $16.21M | $10.65M | (m) | 21.37× |
| 2018-09-30 | $145.94M | $26.90M | $104.25M | (m) | $5.75M | $12.11M | $10.11M | $9.35M | 5.43× |
| 2018-06-30 | $38.74M | $62.85M | $25.33M | (m) | $1.76M | $6.75M | $13.21M | $9.13M | 0.62× |
| 2017-12-31 | $12.40M | $50.22M | $2.32M | (m) | $983.00K | $7.42M | $5.56M | $9.43M | 0.25× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |